title: Relationship between ulcerative colitis patients treated with leukocytapheresis and ulcerative colitis-associated colorectal cancer.
abstract: BACKGROUND
  Leukocytapheresis (LCAP) is a recent modality for treatment of patients with ulcerative colitis (UC). This study aimed to assess whether LCAP changed the development of colorectal cancer (CRC) in patients with UC.
  
  
  METHODS
  A total of 42 patients with UC underwent surgical treatment from January 2001 until October 2010 at Kurume University Hospital. The patient details, preoperative therapy, operative indication and complications were obtained from our prospective database. Univariate, multivariate analysis and tree model were used for statistical analysis.
  
  
  RESULTS
  In patients who received LCAP before surgery, CRC was significantly less frequent (p=0.0321). CRC incidence following LCAP increased when the disease period from diagnosis of UC exceeded 133 months. Multivariate analysis showed that the odds for undergoing LCAP were significantly higher (p=0.0305) in those cases with a total dose of steroid more than 2.57 g.
  
  
  CONCLUSIONS
  LCAP may suppress CRC in UC patients.
authors.affiliation: Department of Surgery, Faculty of Medicine, Kurume University, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan. kinugasa_tetsushi@med.kurume-u.ac.jp
authors.forename: Tetsushi
authors.initials: T
authors.lastname: Kinugasa
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Akagi
authors.forename: Kenta
authors.initials: K
authors.lastname: Murotani
authors.forename: Kansakar
authors.initials: K
authors.lastname: Romeo
authors.forename: Takefumi
authors.initials: T
authors.lastname: Yoshida
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Ryu
authors.forename: Ichitarou
authors.initials: I
authors.lastname: Shiratuchi
authors.forename: Kazuo
authors.initials: K
authors.lastname: Shirouzu
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D003093:Colitis, Ulcerative / Q000150:complications / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D015179:Colorectal Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D003131:Combined Modality Therapy; D004198:Disease Susceptibility; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D015994:Incidence; D007937:Leukapheresis; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents